{"id":"W2136385642","doi":"10.1517/14712598.2012.657622","title":"Obinutuzumab for the treatment of lymphoproliferative disorders","year":2012,"lang":"en","type":"review","venue":"Expert Opinion on Biological Therapy","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Cancer Foundation; University of Calgary","funders":"","keywords":"Obinutuzumab; Rituximab; Medicine; Antibody-dependent cell-mediated cytotoxicity; CD20; Clinical trial; Lymphoma; Oncology; Monoclonal antibody; Immunology; Monoclonal antibody therapy; Internal medicine; Antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005425973,0.000921827,0.001415674,0.00245024,0.0002636761,0.0007999082,0.0008694797,0.001010983,0.005049552],"category_scores_gemma":[0.0005817722,0.0002125638,0.0005513356,0.002251023,0.0004033506,0.0008397659,0.0006310182,0.001606671,0.003458002],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006460807,"about_ca_system_score_gemma":0.0008846691,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009401933,"about_ca_topic_score_gemma":0.00157153,"domain_scores_codex":[0.999767,0.00004377987,0.00002842523,0.00004078017,0.00009754224,0.00002241837],"domain_scores_gemma":[0.9997715,0.00008192161,0.00005347125,0.000006681061,0.00006118261,0.00002521024],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000736539,0.0000488427,0.00008763133,0.01349553,0.00009773222,0.0001989306,0.00003487094,0.0002326973,0.001222175,0.001190392,0.03434534,0.9489722],"study_design_scores_gemma":[0.00004694856,0.00007483971,0.0005451735,0.004276083,0.0001359686,0.001740295,0.00002693289,0.00006449648,0.0003964558,0.001108576,0.9915721,0.00001217938],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00006685931,0.99878,0.00006431361,0.0001776355,0.0001696145,0.000004883749,0.00001103818,0.00000497995,0.0007206741],"genre_scores_gemma":[0.0006390788,0.9981363,0.0001260855,0.0002254555,0.0001968387,0.000007353364,0.00003200382,0.000001438337,0.0006353607],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.005049552,"threshold_uncertainty_score":0.01689243,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2809002386474803,"score_gpt":0.4416714715049894,"score_spread":0.1607712328575091,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}